CSBio CSBio

X
[{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Reports Topline Results from Two Pivotal Clinical Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Crescita Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology

            Lead Product(s): CTX-101

            Therapeutic Area: Dermatology Product Name: CTX-101

            Highest Development Status: Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY